Company profile
ProKidney Corp.
NASDAQ: PROK · Healthcare · Biotechnology
#882 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
41DFH 46DQ 29GM —SS 57
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), balance-sheet leverage · ↓ Piotroski F, disclosure history
Methodology →Revenue TTM
$818.0k
Rev growth YoY (TTM)
+55.2%
Net income (FY)
-$69.0M
Employees
231
as of 2026-08-11
Market cap
$568.3M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$893.0k$893.0k2025
Net income-$69.0M-$69.0M2025
Operating income-$165.0M-$165.0M2025
Total assets$335.6M$335.6M2025
Liabilities$34.8M$34.8M2025
Equity-$1.0B-$1.0B2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ProKidney Corp.’s revenue?
ProKidney Corp. booked $893.0k in FY2025 revenue, growing 1075% year over year — faster than 96% of Healthcare companies we track, at a -7725.2% net margin.
Peers · Healthcare
The CannaBusiness Group, Inc.——INDVR Brands Inc.——Quick-Med Technologies, Inc.——InVitro International76B+Profile Solutions, Inc.——IGC Pharma, Inc.45DKey facts
CEOBruce Culleton
SectorHealthcare
IndustryBiotechnology
HeadquartersWinston-Salem, NC
ExchangeNASDAQ: PROK
Employees231
IPO date2021-06-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.